Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
OPUS-2 cenerimod in moderate-to-severe systemic lupus erythematosus
jRCT2051230027Phase 3Completed
- Sponsor
- Idorsia
- Start
- May 2023
- Modality
- Small Molecules
01
Overview
Phase 3, randomised, double-blind trial in systemic lupus erythematosus (SLE) comparing Cenerimod + background therapy with Placebo + background therapy (2 arms). Primary endpoint: Change from baseline to Month 12 in modified Systemic Lupus Erythematosus Disease Activity Index-2000 score. Started May 2023; status: completed.
02
Drugs
cenerimod
03
Conditions
systemic lupus erythematosus (SLE)
Beyond the preview
Go deeper on jRCT2051230027.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on jRCT2051230027.